Abstract:Individuals with sickle cell disease (SCD) experience many complications and health problems due to their mutated hemoglobin gene; however, these problems could be alleviated by using CRISPR gene editing to alter which hemoglobin variants hematopoietic stem progenitor cells produce. The aim of this review is to determine if it is safe and effective to treat patients with SCD with CRISPR. The findings of “CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β Thalassemia” found an increase in fetal hemoglobin expression in patients after transplanting hematopoietic stem progenitor cells with edits to the BCL11A transcription factor. “Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia” also raised fetal hemoglobin by editing hematopoietic stem progenitor cells within their β-globin loci to artificially apply a hereditary persistence of fetal hemoglobin deletional genotype to the cells. Researchers in “CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells” raised wild-type hemoglobin expression in hematopoietic stem progenitor cells affected with SCD by editing the β-globin loci and “fixing” the point mutation that causes SCD. Target deletion efficiency ranged from 18%-80%, and every study used either SpCas9 or SaCas9. Each study found no punitive off-target effects, and they also succeeded in raising hematopoietic stem progenitor cells levels of their targeted hemoglobin. These results point to using CRISPR as both a safe and effective way to treat SCD.

Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease

Treating Sickle Cell Disease: Gene Therapy Approaches

Therapeutic Gene Editing for Hemoglobinopathies

Current state of gene therapy in sickle cell disease

Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease

Hematopoietic stem cell collection for sickle cell disease gene therapy

Gene Therapies for Sickle Cell Disease

Curative Therapies for Sickle Cell Disease

In vivo HSC prime editing rescues Sickle Cell Disease in a mouse model

Hematopoietic Stem Cell Transplantation in Sickle Cell Disease: A Multidimentional Review

Using Crisper in the Treatment of Sickle Cell Disease

Use of genome-editing tools to treat sickle cell disease

[Development of hematopoietic stem cell-targeted gene therapy]

Gene therapy using haematopoietic stem and progenitor cells

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.

Non-viral DNA delivery and TALEN editing correct the sickle cell mutation in hematopoietic stem cells

Cell and Gene Therapy for Anemia: Hematopoietic Stem Cells and Gene Editing

Current and Future Therapeutics for Treating Patients with Sickle Cell Disease

Sickle Cell Disease: From Genetics to Curative Approaches

Seamless correction of the sickle cell disease mutation of the HBB gene in human induced pluripotent stem cells using TALENs.

Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34+ cell therapy to induce fetal hemoglobin for sickle cell disease